https://www.selleckchem.com/products/genipin.html
0%) and fatigue (n=5, 11.1%). By Response Evaluation Criteria In Solid Tumors (RECIST), four of 10 (40.0%) patients with MET-amplified tumors had confirmed partial response in target lesions (one ovarian, two gastric, and one esophageal), two (20.0%) had stable disease, three (30.0%) had progressive disease; one patient was unable to be evaluated. Among patients with nonamplified tumors (n=35), no objective responses were observed; however, 11 patients had stable disease per RECIST criteria. In conclusion, telisotuzumab has an acceptabl
Like
Comment
Share
